drugset / Trial / NCT04674774
Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
This study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycline for 14 days (TBMT) and PPI, bismuth, metronidazole, and tetracycline for 14 days (LBMT)
Timeline
- Start
- 2021-03-04
- Primary completion
- 2022-02-28
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lansoprazole | Other / unclassified | 30 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 50 mg | Oral |
| Background | Bismuth Potassium Citrate | Unknown | 300 mg | Oral |
| Background | Metronidazole | Small molecule | 500 mg | Oral |
| Background | Tetracycline | Unknown | 500 mg | Oral |